Abstract
Solid oral modified-release dosage forms provide numerous advantages for drug delivery compared to dosage forms where the drugs are released and absorbed rapidly following ingestion. Natural polymers are of particular interest as drug carriers due to their good safety profile, biocompatibility, biodegradability, and rich sources. This review described the current applications of important natural polymers, such as chitosan, alginate, pectin, guar gum, and xanthan gum, in solid oral modified-release dosage forms. It was shown that natural polymers have been widely used to fabricate solid oral modified-release dosage forms such as matrix tablets, pellets and beads, and especially oral drug delivery systems such as gastroretentive and colon drug delivery systems. Moreover, chemical modifications could overcome the shortcomings associated with the use of natural polymers, and the combination of two or more polymers presented further advantages compared with that of single polymer. In conclusion, natural polymers and modified natural polymers have promising applications in solid oral modified-release dosage forms. However, commercial products based on them are still limited. To accelerate the application of natural polymers in commercial products, in vivo behavior of natural polymers-based solid oral modified-release dosage forms should be deeply investigated, and meanwhile quality of the natural polymers should be controlled strictly, and the influence of formulation and process parameters need to be understood intensively.
Keywords: Natural polymers, modified release, chitosan, alginate, pectin, guar gum, xanthan gum, solid oral dosage forms.
Current Pharmaceutical Design
Title:Applications of Natural Polymeric Materials in Solid Oral Modified-Release Dosage Forms
Volume: 21 Issue: 40
Author(s): Liang Li, Xin Zhang, Xiangqin Gu and Shirui Mao
Affiliation:
Keywords: Natural polymers, modified release, chitosan, alginate, pectin, guar gum, xanthan gum, solid oral dosage forms.
Abstract: Solid oral modified-release dosage forms provide numerous advantages for drug delivery compared to dosage forms where the drugs are released and absorbed rapidly following ingestion. Natural polymers are of particular interest as drug carriers due to their good safety profile, biocompatibility, biodegradability, and rich sources. This review described the current applications of important natural polymers, such as chitosan, alginate, pectin, guar gum, and xanthan gum, in solid oral modified-release dosage forms. It was shown that natural polymers have been widely used to fabricate solid oral modified-release dosage forms such as matrix tablets, pellets and beads, and especially oral drug delivery systems such as gastroretentive and colon drug delivery systems. Moreover, chemical modifications could overcome the shortcomings associated with the use of natural polymers, and the combination of two or more polymers presented further advantages compared with that of single polymer. In conclusion, natural polymers and modified natural polymers have promising applications in solid oral modified-release dosage forms. However, commercial products based on them are still limited. To accelerate the application of natural polymers in commercial products, in vivo behavior of natural polymers-based solid oral modified-release dosage forms should be deeply investigated, and meanwhile quality of the natural polymers should be controlled strictly, and the influence of formulation and process parameters need to be understood intensively.
Export Options
About this article
Cite this article as:
Li Liang, Zhang Xin, Gu Xiangqin and Mao Shirui, Applications of Natural Polymeric Materials in Solid Oral Modified-Release Dosage Forms, Current Pharmaceutical Design 2015; 21 (40) . https://dx.doi.org/10.2174/1381612821666151008150306
DOI https://dx.doi.org/10.2174/1381612821666151008150306 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Characterization of Impurities - Use of Hyphenated LC-MS Technique
Current Pharmaceutical Analysis Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Current Drug Targets Gene Patents Related to Common Diseases of the Eye
Recent Patents on DNA & Gene Sequences Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Emerging Novel Treatment Strategies for Diabetic Eye Diseases
Current Diabetes Reviews Insulin Modulates <i>In Vitro Secretion</i> of Cytokines and Cytotoxins by Human Glial Cells
Current Alzheimer Research Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis
Current Pharmaceutical Biotechnology PUFA Supplements and Type 2 Diabetes in the Elderly
Current Pharmaceutical Design P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences
Recent Patents on Cardiovascular Drug Discovery COVID-19 in People with Diabetes: Epidemiological Perspectives and Public Health Actions in the Middle East and North Africa (MENA) Region
Current Diabetes Reviews Clozapine Safety, 35 Years Later
Current Drug Safety HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design